Pulmonary Atresia With Ventricular Septal Defect

Etiology

The etiology of PAVSD is not completely elucidated yet, there is a noteworthy connection with genetic syndromes. One research reported a 45% incidence of PAVSD in children with DiGeorge syndrome (22q11 deletion); DiGeorge syndrome is associated with lack of a thymus, which may be evidenced during surgical correction.[8] VATER (VACTERL association) and Alagille syndrome are also implicated in PAVSD; Alagille syndrome associated with PAVSD carries a grave prognosis.[3] 

Several risk factors have been linked with PAVSD:

• History of congenital heart diseases in either parent.
• History of intake of teratogenic drugs by the mother during gestation.
• Smoking during or before pregnancy.
• Poorly controlled diabetes.
• Pregnancy at an older age.

These risk factors are not specific to PAVSD and are also found frequently in other congenital anomalies.

Epidemiology

The incidence of congenital heart diseases is decreasing yearly due to the avoidance of known teratogens and risk factors through patient education and counseling. The incidence of pulmonary atresia is also decreasing. The prevalence of pulmonary atresia in the years 1999 to 2000 was 12.1% of all congenital heart diseases, which gradually decreased to 9.6% in 2008.[4]

Pathophysiology

In PAVSD, the degree of pulmonary artery involvement steers the clinical picture and the treatment options. Presentations include an isolated valvular atresia or proximal pulmonary trunk involvement. The right and left pulmonary arteries may or may not communicate and the intrapericardial pulmonary arteries are often very diminutive (on the order of 1 to 3 mm).[8] Major aortopulmonary collateral arteries (MAPCA) usually supply the lung parenchyma. These MAPCAs may arise from the thoracic or abdominal aorta, subclavian arteries, internal mammary arteries, intercostal arteries, or other less common locations. The systemic-to-pulmonary anastomoses in MAPCAs are classified into extrapulmonary, hilar, lobar, and segmental. MAPCAs are usually aberrant and stenosed at either end. In other instances, patent ductus arteriosus (PDA) may also contribute to supplying pulmonary circulation.

The intrapulmonary arterial structure mainly relies on the size and flow of PDA. In the absence of PDA or with too many aberrant MAPCAs, the intrapulmonary arteries may not be developed properly, leading to pulmonary hypertension. The associated VSD is usually membranous in origin. Other defects, such as atrial septal defects, are not uncommon, but their association with PAVSD is not yet well understood. Pulmonary atresia leads to right ventricular outflow tract obstruction (RVOTO) and an increased resistance against the right ventricular contraction eventually leading to the development of right ventricular hypertrophy, while the left ventricle is usually spared. Coronary artery anomalies are not a common occurrence in PAVSD but coronary fistulas may rarely be present.[5][6]

The pulmonary atresia and the resulting RVOTO are responsible for the right-to-left shunt in PAVSD. A critical balance between systemic and pulmonary vascular resistance is necessary for normal perfusion. A sudden decrease in systemic vascular resistance can lead to cyanotic spells, similar to the ones described in the Tetralogy of Fallot. Conversely, some children may present with signs and symptoms of pulmonary overcirculation and congestive heart failure.[8]

The overriding position of the aorta has a compensatory role by receiving the blood from both the ventricles and delivering it to the systemic and pulmonary circulation via the patent ductus arteriosus. Patency of ductus arteriosus is crucial in the initial survival of these patients. In mild to moderate cases where the pulmonary vasculature and valve are mildly atretic, the right ventricle may be able to pump adequate blood in the native pulmonary circuit for oxygenation. PDA, in these cases, may spontaneously collapse before presentation.

About 75% of neonates have standard anatomy described above; however, certain features have been described that may indicate a deviation from conventional management. These features include the following: 1) PDA to one lung with MAPCAs to the other lung 2) hemi-truncus to one lung with MAPCAs to the other lung 3) dual supply to the lung from MAPCAs and the pulmonary arterial tree.[7] Patients in the latter category of dual supply with all 18 lung segments receiving pulmonary artery blood flow may be candidates for a neonatal aortopulmonary window, allowing the pulmonary arteries to grow and avoid the need for MAPCA surgery, although some of these patients may require treatment for pulmonary artery stenoses.[8] 

History and Physical

Although evident in fetal ultrasound at 18 to 22 weeks gestation, many cases may go unrecognized where the mother refuses prenatal care or does not have access to the appropriate maternal healthcare resources. In these situations, the case may be first recognized on physical examination, usually at birth. The clinical presentation of the PAVSD is highly variable depending on the degree of pulmonary atresia and MAPCAs. Most neonates present with cyanosis and cardiac murmur.[9]  Other common symptoms include the following:

• Central cyanosis may present as bluish discoloration of the face, particularly around the mouth and lips. In severe cases, it may be seen in peripheral limbs as well.
• Increased respiratory rate or shortness of breath due to poor blood oxygenation. It may not be evident at rest and only present at exertion, ie, during crying or breastfeeding.
• Easy fatigability may present as a weak cry, tone loss, and poor breast latching.
• Failure to thrive.
• Difficulty feeding.

The physical exam may reveal central cyanosis, a holosystolic murmur at the left sternal border that may radiate to the back or axilla, a single accentuated second heart sound S2, a machine-like continuous murmur of PDA best heard at the upper precordium or the interscapular region on the back, a weak grip, a low weight for age, and lethargy.[6]

Peripheral edema, clubbing, and worsening cyanosis may indicate congestive heart failure (CHF), especially if presenting late in life. A small number of neonates/infants present with CHF early in life. They have large MAPCAs with excessive pulmonary blood flow, sometimes requiring mechanical ventilation. These patients require early complete repair, and because they often have well-developed pulmonary vasculature, outcomes are generally favorable.[8]

Evaluation

The following investigations are a part of the comprehensive evaluation of PAVSD patients:

• Echocardiography: The gold standard investigation module, this provides valuable insight into pulmonary valve atresia, overriding of the aorta, VSD, ASD, some MAPCA if present, the pressure gradient across valves, and ejection fraction.[6]
• Angiography: Cardiac catheterization is another important investigation. It can provide details of the anatomy, size, and distribution of the arterial vasculature. It can assess pressures in the right ventricle, and the pressure gradient across the pulmonary valve. MAPCAs can be confirmed by catheterization and selective injections of contrast into collateral vessels to provide the most accurate demonstration of pulmonary blood supply to lung segments. Central pulmonary arteries (PAs) can be identified only if there is a patent arterial duct or connection to a collateral. In recent years, CTA has been used in place of angiography.[7]
• Pulse oximetry to evaluate oxygen saturation, especially in dark-skinned infants where cyanosis may be missed on physical exam. A hyperoxia test conducted at birth can easily single out infants with cyanotic heart diseases and facilitate early management.
• Arterial blood gasses.
• Baseline hemoglobin and blood cell indices.
• Genetic testing particularly if other congenital defects are present.
• Traditional chest X-ray signs include absent pulmonary artery shadow, boot-shaped heart, cardiomegaly, or poor lung vasculature markings.
• Magnetic resonance angiography (MRA) or computed tomography angiography (CTA) is important to delineate vascular anatomy before surgery to plan correction and may reveal other MAPCAs that are difficult to see on echocardiography.[10]

Treatment / Management

Medical management: Oxygen saturation is critical and should be monitored continuously. Similarly, fluid imbalance and acidosis, if present, need to be addressed urgently. Since the neonate is usually unable to feed well, nutritional rehabilitation might be needed as well. In severe cases where the pulmonary valve is completely atretic and the pulmonary circulation is entirely dependent on ductus arteriosus, prostaglandin E1 should be considered to keep the duct open until a surgical correction can take place. Symptomatic treatment with diuretics or digoxin is indicated if the patient is going into congestive heart failure. 

Surgical management: Conventional treatment, occurring in about 75% of cases, involves discharge of the neonates from the hospital to return at 3 to 6 months of age when their organs are more developed.[7] Mainly, the size of the pulmonary arteries, presence/absence of MAPCAs, and PDA drive the surgical plan. Out of these criteria, PAVSD can be divided into two main categories: PAVSD with ductus-dependent pulmonary blood flow and PAVSD with MAPCAs-dependent pulmonary blood flow.

• PAVSD with MAPCAs
  • PAVSD with under-developed MAPCAs:
    • Primary rehabilitation:  An initial procedure targeting small MAPCAs, aiming at improving the central PAs with either a prosthetic central shunt or the reimplantation of the main pulmonary artery (PA) on the side of the aorta, “the Melbourne shunt,” or a patching of the outflow tract.
      1. Central shunt: (Laks technique).
      2. Side reimplantation (Melbourne).
      3. Right Ventricular Outflow Tract Patching.
    • Secondary rehabilitation:
      1. Right ventricle to pulmonary artery shunt (Sano).
      2. Pulmonary artery patching.
    • Final repair: Involves repair patching of pulmonary arteries and VSD closure.
  • PAVSD with well-developed MAPCAs
    • Unifocalization: This involves reattaching MAPCAs to central pulmonary arteries.[11]
      • One follow-up study found a 95% patency rate of MAPCAs with the midline unifocalization approach by catheterization (although 20% of these had some degree of stenosis).[12] 
      • Risk factors for needing reoperation of a unifocalized bed include the following:[7]
        • a) Unifocalization/shunt rather than complete repair
        • b) Higher initial right ventricle-to-aorta pressure ratios
        • c) Absence of central pulmonary arteries
    • VSD Closure.
• PAVSD with patent arterial duct: This type of lesion is treated the same way as tetralogy of Fallot.
  • Staged Palliation: The surgical treatment of PAVSD with ductus-dependent pulmonary circulation is a staged approach that involves several admissions and many operations without any fixed number. The steps of correction are as follows:

1) Blood flow is established first in the pulmonary arteries by connecting it directly to the aorta through a modified Blalock-Taussig-Thomas shunt.

2) The right ventricle can also be connected to the aorta temporarily if the overriding of the aorta is insufficient (Sano shunt).

3) As the pulmonary arteries grow in size due to sustained blood supply from the aorta, the pulmonary circulation is then connected to the pulmonary artery.

4) The right ventricle is connected back to the pulmonary artery.

5) The MAPCAs are closed in the next step, usually at 6 months of age, if the respective lung segments are receiving enough supply through the now-developed pulmonary arteries.

6) VSD is repaired at the end, usually at age 1 to 3 years. The major benefit of this approach is the whole procedure becomes more tolerable by the already feeble neonate and breaks are available to allow for healing. In contrast to staged repair, the other approach is complete repair in one surgery. This procedure is only suitable for limited candidates who are on the low end of the severity spectrum. One high-volume center found that infants with a basal oxygen saturation higher than 85% have well-developed pulmonary vasculature amenable to single-stage intervention.[7]

Early Total Correction

In this less popular approach preferred mostly in mild cases, surgeons usually correct the anatomy within the same admission if not the same operation. The patients are carefully picked, and risks versus benefits are critically analyzed before choosing this option. Some centers have found lower mortality and intervention rates with single-stage total correction.[11] 

As noted above, neonates with frank CHF symptoms may require early correction. In addition, infants with persistent PDA or hemi-truncus can develop pulmonary vascular obstructive disease, also requiring early correction.[7]

Perioperative Care

Improved outcomes have been associated with early anticoagulation to decrease thrombotic occlusion of shunts; one suggested dose is 10 mg/kg of aspirin (ASA). Another suggestion is improved post-surgical care with frequent clinic visits to re-dose ASA and caregiver education regarding the symptoms of shunt failure with 24-hour medical availability by phone.[13]

Cardiac Transplant

In patients with the completely atretic pulmonary system, or who have failed the surgical corrective measures, a cardiac transplant can be the viable option.[6](B3)

Differential Diagnosis

Differential diagnoses of PAVSD include the following:[14][15]

• Severe tetralogy of Fallot
• Transposition of the great arteries with pulmonary stenosis
• A single ventricle with severe pulmonary stenosis 
• Tricuspid atresia
• Pulmonary atresia with intact interventricular septum
• Double-outlet right ventricle with pulmonary atresia
• Double-inlet left ventricle with pulmonary atresia
• Congenitally corrected transposition of the great arteries (L-TGA) with ventricular septal defect and pulmonary atresia

Prognosis

Without surgical correction, about 50% of patients die within the first two years of life, and 20-year survival is around 10%.[10] With proper treatment and follow-up, 65% of the patients who are alive at 1 year can live beyond the age of 10.[9] One high-volume center estimated operative mortality at 1.5% to 8% depending on the procedure performed.[7] 

Complications

On top of surgical and anesthesia complications in treated patients, some of the complications of PAVSD are:

• Congestive heart failure (CHF)
• Reactive erythrocytosis in response to chronic hypoxia
• Infective endocarditis due to the aberrant flow of blood
• Sepsis either due to infective endocarditis or poor immune system development
• Delayed growth and puberty
• Arrhythmias
• Sudden death